MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2026.1894178

Медицинская библиотека · Frontiers in immunology · 2026

Oncolytic virus-mediated GPC3 delivery overcomes antigen heterogeneity in hepatocellular carcinoma and enhances GPC3-directed immunotherapy.

Chaurasiya Shyambabu, Kim Sang-In, Sah Prakash, Zhang Zhifang, Vashi Yoya, Wu Hannah, Cillis Jennifer, Park Anthony, Yang Annie, Woo Yanghee, Xiong Guangyang, Liu Jingbao, Zhang Hongbing, Wang Pei, Liu Cheng, Fong Yuman

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide and is characterized by substantial molecular and immunologic heterogeneity that contributes to therapeutic resistance and poor clinical outcomes. Glypican-3 (GPC3) is an attractive immunotherapy target in HCC; however, its heterogeneous expression limits the effectiveness of GPC3-directed approaches. ECT204, a GPC3-directed ARTEMIS® T-cell therapy, has shown improved safety compared with conventional CAR T cells but remains dependent on sufficient tumor-associated GPC3 expression. In this study, we investigated whether an oncolytic virus could be used to selectively deliver GPC3 to tumor cells to expand the applicability of GPC3-targeted immunotherapies.

METHODS

We engineered the oncolytic vaccinia virus CF33-GPC3 to express GPC3 and evaluated its ability to sensitize GPC3-negative tumor cells to ECT204 in vitro and in vivo using GPC3-knockout HepG2 xenograft models. We also assessed the compatibility with other GPC3-targeted immunotherapies, including a bispecific T-cell engager (BiTE) and the monoclonal antibody codrituzumab.

RESULTS

CF33-GPC3 efficiently induced surface expression of GPC3 in previously GPC3-negative tumor cells, resulting in activation of GPC3-directed ECT204 T cells and subsequent tumor cell killing. In vivo, combination therapy with CF33-GPC3 and ECT204, administered either intratumorally or intravenously, achieved significantly greater tumor control than either monotherapy alone. Moreover, OV-mediated GPC3 expression sensitized tumor cells to killing by GPC3-specific BiTE-redirected T cells and enhanced codrituzumab-mediated NK cell cytotoxicity.

CONCLUSIONS

These findings demonstrate that OV-mediated GPC3 delivery can overcome antigen heterogeneity in HCC and broaden the applicability of GPC3-directed immunotherapies.

Для цитирования: Chaurasiya Shyambabu, Kim Sang-In, Sah Prakash, Zhang Zhifang, Vashi Yoya, Wu Hannah, Cillis Jennifer, Park Anthony, Yang Annie, Woo Yanghee, Xiong Guangyang, Liu Jingbao, Zhang Hongbing, Wang Pei, Liu Cheng, Fong Yuman. Oncolytic virus-mediated GPC3 delivery overcomes antigen heterogeneity in hepatocellular carcinoma and enhances GPC3-directed immunotherapy.. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1894178.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.